Medical
Mesothelioma Second-Line Treatment 2026: 4 Evidence-Based Pathways After First-Line Therapy
David Foster
May 6, 2026
After first-line chemo or immunotherapy fails, mesothelioma patients have 4 evidence-based 2L options. Gemcitabine-ramucirumab leads with 13.8-month OS.
11 min read 7 FAQs
Read